Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we profiled the humoral immune response in a cohort of non-human primates immunized with a recombinant SARS-CoV-2 spike glycoprotein (NVX-CoV2373) at two doses, administered as a single- or two-dose regimen. Both antigen dose and boosting significantly altered neutralization titers and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were associated with distinct levels of protection in the upper and lower respiratory tract. Moreover, NVX-CoV2373 elicited antibodies that functionally targeted emerging SARS-CoV-2 variants. Collectively, the data presented here suggest that a single dose may prevent disease via combined Fc/Fab functions but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Preliminary retrospective analysis of the first dose of the Pfizer/BNT162b2 before boosting suggested approximately a 52% protection from severe infection, whereas more-recent studies have suggested a single dose is 85% effective at preventing death.(5,46,47) In addition, recent results from Johnson and Johnson’s sing…”
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Research works printed but not linked: 39
- Huff, 2020, Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies, Clin. Infect. Dis., 71, 2752, 10.1093/cid/ciaa654 · DOI · Paper page
- Day, 2020, Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village, BMJ, 368, m1165, 10.1136/bmj.m1165 · DOI · Paper page
- Meng, 2020, Intubation and ventilation amid the COVID-19 outbreak: Wuhan’s experience, Anesthesiology, 132, 1317, 10.1097/ALN.0000000000003296 · DOI · Paper page
- Poland, 2020, SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates, Lancet, 396, 1595, 10.1016/S0140-6736(20)32137-1 · DOI · Paper page
- 2021, UK science advisers: publish evidence behind COVID vaccine changes, Nature, 589, 169, 10.1038/d41586-021-00045-8 · doi:10.1038/d41586-021-00045-8
- Loos, 2020, Evolution of early SARS-CoV-2 and cross-coronavirus immunity, MSphere, 5, e00622-20, 10.1128/mSphere.00622-20 · DOI
- Brunet-Ratnasingham, 2021, Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality, medRxiv
- Bournazos, 2017, Diversification of IgG effector functions, Int. Immunol., 29, 303, 10.1093/intimm/dxx025 · DOI · Paper page
- Bournazos, 2015, Fcγ receptor pathways during active and passive immunization, Immunol. Rev., 268, 88, 10.1111/imr.12343 · DOI · Paper page
- Bournazos, 2020, The role of IgG Fc receptors in antibody-dependent enhancement, Nat. Rev. Immunol., 20, 633, 10.1038/s41577-020-00410-0 · DOI · Paper page
- Crowley, 2019, Mind the gap: how interspecies variability in IgG and Its receptors may complicate comparisons of human and non-human primate effector function, Front. Immunol., 10, 697, 10.3389/fimmu.2019.00697 · DOI · Paper page
- Plotkin, 2021, Accelerate COVID-19 vaccine rollout by delaying the second dose of mRNA vaccines, Clin. Infect. Dis., ciab068
- Kadire, 2021, Delayed second dose versus standard regimen for COVID-19 vaccination, N. Engl. J. Med., 384, e28, 10.1056/NEJMclde2101987 · DOI
- Matrajt, 2021, Optimizing vaccine allocation for COVID-19 vaccines: critical role of single-dose vaccination, medRxiv
- Barrett, 2021, Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses, Nat. Med., 27, 279, 10.1038/s41591-020-01179-4 · DOI · Paper page
- Tauzin, 2021, A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses, bioRxiv
- Ullah, 2021, Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy, bioRxiv
- Mahase, 2020, Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows, BMJ, 371, m4826, 10.1136/bmj.m4826 · DOI
- Ledford, 2021, J&J’s one-shot COVID vaccine offers hope for faster protection, Nature
- Iwasaki, 2017, Early local immune defences in the respiratory tract, Nat. Rev. Immunol., 17, 7, 10.1038/nri.2016.117 · DOI · Paper page
- Subbarao, 2020, Respiratory virus infections: understanding COVID-19, Immunity, 52, 905, 10.1016/j.immuni.2020.05.004 · DOI · Paper page
- Sealy, 2016, Antibody-secreting cells in respiratory tract tissues in the absence of eosinophils as supportive partners, Int. Immunol., 28, 559, 10.1093/intimm/dxw035 · DOI
- Kato, 2013, B-lymphocyte lineage cells and the respiratory system, J. Allergy Clin. Immunol., 131, 933, 10.1016/j.jaci.2013.02.023 · DOI · Paper page
- Chiu, 2015, Antiviral B cell and T cell immunity in the lungs, Nat. Immunol., 16, 18, 10.1038/ni.3056 · DOI
- Callaway, 2020, The coronavirus is mutating—does it matter?, Nature, 585, 174, 10.1038/d41586-020-02544-6 · DOI · Paper page
- Lee, 2020, Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant, bioRxiv
- Santos, 2021, The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation, bioRxiv
- Mahase, 2020, Covid-19: What have we learnt about the new variant in the UK?, BMJ, 371, m4944, 10.1136/bmj.m4944 · DOI
- Zhou, 2021, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell, 184, 2348, 10.1016/j.cell.2021.02.037 · DOI · Paper page
- Corey, 2020, A strategic approach to COVID-19 vaccine R&D, Science, 368, 948, 10.1126/science.abc5312 · DOI · Paper page
- Chandrashekar, 2020, SARS-CoV-2 infection protects against rechallenge in rhesus macaques, Science, 369, 812, 10.1126/science.abc4776 · DOI · Paper page
- Yu, 2021, Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques, Nature, 596, 423, 10.1038/s41586-021-03732-8 · DOI
- Alter, 2021, Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans, Nature, 596, 268, 10.1038/s41586-021-03681-2 · DOI · Paper page
- Lövgren, 1988, The requirement of lipids for the formation of immunostimulating complexes (iscoms), Biotechnol. Appl. Biochem., 10, 161, 10.1111/j.1470-8744.1988.tb00012.x · doi:10.1111/j.1470-8744.1988.tb00012.x
- Butler, 2019, A sample-sparing multiplexed ADCP assay, Front. Immunol., 10, 1851, 10.3389/fimmu.2019.01851 · DOI
- Karsten, 2019, A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis, J. Immunol. Methods, 471, 46, 10.1016/j.jim.2019.05.006 · DOI · Paper page
- Fischinger, 2019, A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation, J. Immunol. Methods, 473, 112630, 10.1016/j.jim.2019.07.002 · DOI · Paper page
- Gunn, 2018, A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus, Cell Host Microbe, 24, 221, 10.1016/j.chom.2018.07.009 · DOI · Paper page
- Brown, 2017, Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles, J. Immunol. Methods, 443, 33, 10.1016/j.jim.2017.01.010 · DOI · Paper page
Cited by
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa
Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A. J., Blumberg, L., Welch, R., Ngorima-Mabhena, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119658 · Cited by 366
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
Goldblatt, D., Alter, G., Crotty, S., & Plotkin, S. A. (2022) · Immunological Reviews · doi:10.1111/imr.13091 · Cited by 298
Self-citationSARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.005 · Cited by 273
Self-citationScheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Liang, C.-Y., Jani, H., Martin, P., Amato, N. J., Avena, L. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02092-8 · Cited by 169
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Mok, C. K. P., Cohen, C. A., Cheng, S. M. S., Chen, C., Kwok, K., Yiu, K., Chan, T., Bull, M., Ling, K. C., Dai, Z., et al. (2022) · Respirology · doi:10.1111/resp.14191 · Cited by 162
Metadata
- Authors
- Gorman, M. J., Patel, N., Guebre-Xabier, M., Zhu, A. L., Atyeo, C., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., Yuan, D., Bowman, K. A., Zhou, B., Maciejewski, S., McGrath, M. E., Logue, J., Frieman, M. B., Montefiori, D., Mann, C., Schendel, S., Amanat, F., Krammer, F., Saphire, E. O., Lauffenburger, D. A., Greene, A. M., Portnoff, A. D., Massare, M. J., Ellingsworth, L., Glenn, G., Smith, G., & Alter, G.
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 2
- Issue
- 9
- Pages
- 100405
- ISSN
- 2666-3791 (ISSN-L)
- OpenAlex
- W3198499417
- Cited by
- 129
- References
- 48
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Science Foundation (1745302)
- JPB Foundation (2020-215611 [5384])
- Massachusetts Institute of Technology
- Harvard University
- Icahn School of Medicine at Mount Sinai
- National Institutes of Health (1U01CA260476-01, 3R37AI080289-11S1, CIVIC75N93019C00052, R01AI146785, U19AI135995-02, U19AI42790-02S1)
- Bill and Melinda Gates Foundation (INV-001650, OPP1146996)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. https://app.cochat.ai/papers/10.1016/j.xcrm.2021.100405
- The paper
- Gorman, M. J., Patel, N., Guebre-Xabier, M., Zhu, A. L., Atyeo, C., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., Yuan, D., Bowman, K. A., Zhou, B., Maciejewski, S., McGrath, M. E., Logue, J., Frieman, M. B., Montefiori, D., Mann, C., . . . Alter, G. (2021). Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2021.100405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.